Published in Gene Therapy Weekly, March 2nd, 1998
With the advancement of gene technologies, researchers have been exploring the clinical applications of gene therapy for HIV/AIDS patients. Of the viral products of HIV that might be targeted genetically, disrupting Rev shows promise. Rev is a regulatory protein required for productive viral replication and plays an important role in the activation of virus in infected cells.
In previous research, Clive Woffendin et al. (PNAS 1996;93:2889-94) tested the ability of a mutant inhibitory form of the Rev protein (Rev M10) transduced with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.